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ABSTRACT 
Background and Objectives: Smoking increases inhibition of clopidogrel-induced platelet reactivity in patients 
undergoing elective coronary stenting. However, an association between pre-admission smoking (PS) and post-clo-
pidogrel platelet reactivity in patients with acute myocardial infarction (AMI) has not been determined. Subjects 
and Methods: Study cohorts were recruited from a pool of patients at our hospital who were undergoing coro-
nary stenting for AMI (n=134). Immediately after arrival at the emergency room (ER), all patients received a 600 
mg loading dose of clopidogrel followed by a maintenance dose of 75 mg/day. Platelet aggregation was measured 
with light transmittance aggregometry (LTA) after addition of 5 or 20 μmol/L adenosine diphosphate (ADP). 
Results: Maximal platelet aggregation (Aggmax) was lower in PS patients after 5 μmol/L ADP (43.6±15.7% vs. 
48.4±12.5%, p=0.096) and 20 μmol/L ADP stimuli (56.2±15.6% vs. 61.3±11.6%, p=0.073) compared with 
non-smoking (NS) patients. However, there were no differences in 5 μmol/L (42.6±16.3% vs. 43.8±15.6%, 
p=0.776) and 20 μmol/L ADP-induced Aggmax (54.8±14.3% vs. 56.5±15.9%, p=0.692) between PS patients 
<0.5 pack/day and  ≥0.5 pack/day. Although more PS patients met the criteria for low post-clopidogrel platelet 
reactivity (LPPR) (≤37%; the lowest quartile of 5 μmol/L ADP-induced Aggmax) than NS patients (30.9% vs. 
13.5%, p=0.048), advancing age was the only independent predictor of LPPR {odds ratio (OR) 0.960, 95% 
confidence interval (CI) 0.929 to 0.993, p=0.019}. Conclusion: PS is significantly not associated with decreased 
residual platelet reactivity in AMI patients. (Korean Circ J 2010;40:119-124) 
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Introduction 
 
Clopidogrel is metabolized into an active metabolite 
by 2 consecutive steps involving cytochrome P450 (CYP), 
and inhibits platelet aggregation through an irreversi-
ble blockade of adenosine diphosphate (ADP) P2Y12 
receptors.
1) Therefore, various factors that interfere with 
CYP activity can reduce antiplatelet responses to clopi-
dogrel.
2-5) On the contrary, cigarette smoking, an in-
ducer of CYP1A2 activity, can increase concentrations 
of the active metabolite of clopidogrel.
6) Recently, Bli-
den et al.
7) reported that smoking, in a dose-related 
manner, increases platelet inhibition by clopidogrel com-
pared with non-smoking (NS). An analysis of patients 
on chronic clopidogrel therapy (n=120) showed signi-
ficantly lower platelet aggregation in patients currently 
smoking  ≥0.5 pack/day compared with patients of NS 
and currently smoking <0.5 pack/day (p<0.05). The 
study of Bliden used the results of platelet aggregation 
in the setting of elective coronary stenting. 
However, acute myocardial infarction (AMI) is asso-
ciated with enhanced platelet reactivity, and the impact 
of pre-admission smoking (PS) on post-clopidogrel pla-
telet reactivity in AMI patients can be different from 
platelet reactivity in patients on chronic clopidogrel th-
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erapy. In addition, there is no clear data for the role of 
smoking on clopidogrel-induced platelet inhibition in 
AMI patients.
8)9) Accordingly, the aim of the present 
study was to determine if there is an association between 
smoking and clopidogrel-induced platelet inhibition in 
AMI patients. 
 
Subjects and Methods 
 
Subjects 
Subjects were prospectively recruited from the popu-
lation of patients who underwent, between October 2007 
and May 2008, coronary stenting for AMI in the De-
partment of Cardiology of the Gyeongsang National 
University Hospital. Consecutive patients admitted for 
AMI were enrolled if they were ≥18 years of age and 
had undergone uneventful coronary stenting. AMI was 
defined as clinical symptoms compatible with acute myo-
cardial ischemia within 12 hours before admission with 
a subsequently documented increase in markers of 
AMI. ST-segment elevation myocardial infarction (ST-
EMI) patients were treated with primary stenting less 
than 12 hours after the onset of pain; non-STEMI (NS-
TEMI) patients received coronary stenting within 24 
hours after admission. Exclusion criteria were a history 
of active bleeding and bleeding diatheses, oral anticoa-
gulation therapy with warfarin, contraindications to an-
tiplatelet therapy, left ventricular ejection fraction <30%, 
leukocyte count <3,000/mm
3 and/or a platelet count 
<100,000/mm
3, aspartate aminotransferase or alanine 
aminotransferase levels ≥3 times upper normal, serum 
creatinine level  ≥2.5 mg/dL, and non-cardiac disease 
with a life expectancy <1 year. The Institutional Review 
Board approved the study protocol, and the patients 
provided written informed consent for participation. 
 
Study design 
Immediately after emergency room (ER) arrival, all 
patients received a 600 mg loading dose of clopidogrel 
followed by a maintenance dose of 75 mg/day. Low-
molecular-weight heparin (enoxaparin) or unfractionat-
ed heparin was used at the physician’s discretion before 
the procedure, and tirofiban, which has a short half-life, 
was administered if needed. Pre-discharge post-clopi-
dogrel platelet reactivity was assessed 1) 3 or more days 
after coronary stenting not treated with tirofiban or 2) 
5 or more days after the procedure in patients treated 
with tirofiban. 
 
Platelet function assays and definition 
Platelet aggregation was assessed with light transmit-
tance aggregometry (LTA) according to standard proto-
cols.
10) The results of LTA were validated in our labora-
tory and reported.
11) Blood samples were drawn though 
a 21-gauge needle into vacutainer tubes containing 0.5 
mL sodium citrate 3.2% (Becton-Dickinson, San Jose, 
CA, USA) and processed within 60 minutes. Platelet-
rich plasma (PRP) was obtained as a supernatant fluid 
after centrifuging blood at 120 g for 10 minutes. The 
remaining blood was further centrifuged at 1,200 g for 
10 minutes to prepare platelet-poor plasma (PPP). PRP 
was adjusted to platelet counts of 250,000/μL by add-
ing PPP as needed. Platelet aggregation was assessed at 
37℃ using an AggRAM aggregometer (Helena Labo-
ratories Corp., Beaumont, TX, USA). Light transmis-
sion was adjusted to 0% with PRP and to 100% with 
PPP for each measurement. Platelet functions were meas-
ured after addition of 5 or 20 μmol/L ADP, and curves 
were recorded for 10 minutes. Platelet aggregation was 
measured at peak (Aggmax) and at 5 minutes (Agglate) by la-
boratory personnel blinded to the study protocol. Aggmax 
is considered to reflect the activity of both P2Y1 and 
P2Y12 ADP receptors, whereas Agglate may be more re-
flective of P2Y12 receptor activity. 
We defined the criteria for low post-clopidogrel pla-
telet reactivity (LPPR) as the lowest quartile of 5 μmol/L 
ADP-induced platelet reactivity (Aggmax  ≤37%).
7) 
 
Statistical analysis 
Continuous variables are presented as means±SD. 
They were compared using Student’s unpaired t-tests 
or Mann-Whitney U-tests. Categorical variables are pre-
sented as numbers or percentages and were compared 
using the chi-square tests or Fisher’s exact tests (if an ex-
pected frequency was <5). Platelet function measure-
ments of the 3 groups were analyzed by one-way ana-
lysis of variance (ANOVA) on ranks. To determine pre-
dictors of LPPR, multivariate regression analyses were 
performed using the dependent variables that exhibit-
ed at least a modest effect (p<0.20). A p<0.05 was con-
sidered to indicate a significant difference. Statistical 
analyses were performed using Statistical Package for the 
Social Sciences (SPSS) version 13 (SPSS Inc., Chicago, 
IL, USA). 
 
Results 
 
Baseline characteristics 
We identified 134 AMI patients (73 STEMI and 61 
NSTEMI patients) who underwent uneventful coronary 
stenting. The 134 included 97 PS patients (smoking wi-
thin 2 weeks of the procedure and 37 NS patients (no 
smoking within 1 year of the Procedure). The PS patients 
were younger, more often men, and less likely to have 
diabetes, hypertension or anemia than the NS patients 
(Table 1). 
 
Platelet function assays 
There was no difference between STEMI and NS-
TEMI patients with regard to post-clopidogrel platelet   
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Table 1. Clinical and procedural characteristics 
Variables, n (%)  Pre-admission smoking (n=97)  Non-smoking (n=37)  p 
Age (years)  58.7±12.3 66.1±9.0  <0.001
Male  91 (93.8)  10 (27.9)  <0.001
BMI (kg/m
2) 24.1±2.5 24.9±2.5  <0.179
Indication for intervention      <0.847
STEMI  52 (53.6)  21 (56.8)   
NSTEMI  45 (46.4)  16 (43.2)   
Pre-procedural hemodynamics       
Systolic blood pressure (mmHg)  129±29 125±29  <0.551
Diastolic blood pressure (mmHg)  80±17 76±19  <0.168
Heart rate (bpm)  79±22 81±26  <0.510
Risk factor       
Diabetes mellitus  21 (21.6)  17 (45.9)  <0.009
Hypertension  34 (35.1)  22 (59.5)  <0.018
Hypercholesterolemia  32 (33.0)  14 (37.8)  <0.685
Chronic kidney disease  9 (9.3)  8 (21.6)  <0.079
History      
Previous myocardial infarction  2 (2.1)  0 (0)  <0.523
Previous PCI  1 (1.0)  0 (0)  <0.724
Previous CABG  0 (0)  0 (0)  <1.000
Previous stroke  1 (1.0)  0 (0)  <0.724
Concomitant medications       
Statin     <0.557
CYP 3A4 pathway metabolized  90 (92.8)  34 (91.9)   
Non-CYP 3A4 pathway metabolized  7 (7.2)  3 (8.1)   
Beta blocker  88 (90.7)  31 (83.8)  <0.200
ACEI  25 (25.8)  9 (24.3)  <1.000
ARB  71 (73.2)  26 (70.3)  <0.829
Nitrate  85 (87.6)  33 (89.2)  <0.533
Calcium channel blocker  9 (9.3)  3 (8.1)  <0.567
LV ejection fraction (%)  56±9 56±12  <0.959
Hemoglobin (g/dL)  14.7±1.4 13.9±1.4  <0.002
Platelet count (×10
3/mm
3) 277±63 277±79  <0.993
HbA1C (%)  6.2±1.2 6.8±1.6  <0.019
Creatinine clearance (mL/min)  85±24 76±29  <0.054
Total cholesterol (mg/dL)  192±41 197±43  <0.502
Total ischemic time (minutes) (STEMI patients)  220±180 179±179  <0.575
DTB time (minutes) (STEMI patients)  68±32 62±30  <0.745
Infarct-related vessel      <0.731
Left anterior descending  45 (46.4)  15 (40.5)   
Left circumflex artery  23 (23.7)  11 (29.7)   
Right coronary artery  29 (29.9)  11 (29.7)   
Left main  0 (0)  0 (0)   
Initial TIMI flow grade      <0.249
0 or 1  60 (61.8)  25 (69.4)   
2  28 (28.9)  10 (27.8)   
3  9 (9.3)  1 (2.8)   
Thrombus present  25 (25.8)  4 (10.8)  <0.065
Pre-dilatation  93 (95.9)  35 (94.6)  <0.530
Aspiration thrombectomy  22 (22.7)  4 (10.8)  <0.147
Administration of GPI  8 (8.2)  1 (2.7)  <0.232 
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reactivity (data not shown). When platelet reactivity was 
compared according to clinical risk factors, there were 
no significant differences in terms of the presence of di-
abetes mellitus, hypertension and hypercholesterole-
mia, except for higher values in patients with chronic 
kidney disease (5 μmol/L ADP-induced Aggmax; 52.6
±11.0% vs. 43.8±15.2%, p=0.023 and 20 μmol/L 
ADP-induced Aggmax; 63.6±10.4% vs. 56.7±15.1%, 
p=0.074). The PS patients showed a trend toward lower 
Aggmax after 5 μmol/L (43.6±15.7% vs. 48.4±12.5%, 
p=0.096) and 20 μmol/L ADP stimuli (56.2±15.6% 
vs. 61.3±11.6%, p=0.073) compared with NS patients 
(Table 2). However, Agglate did not differ between PS 
and NS patients (5 μmol/L ADP: 33.8±19.5% vs. 
38.1±17.3%, p=0.234 and 20 μmol/L ADP: 45.5±
22.5% vs. 51.0±18.6%, p=0.187). In contrast to the 
results of Bliden et al.,
7) our results did not show sig-
nificant differences in 5 μmol/L (Aggmax: p=0.776 and 
Agglate: p=0.540) and 20 μmol/L ADP-induced plate-
let aggregation (Aggmax: p=0.692 and Agglate: p=0.517) 
between PS patients <0.5 pack/day and ≥0.5 pack/ 
day (Table 2). 
 
Predictor of low post-clopidogrel platelet reactivity 
More PS patients met the criteria for LPPR than NS 
patients (30.9% vs. 13.5%, p=0.048). To identify sig-
nificant predictors of LPPR, a logistic regression analy-
sis was used to evaluate the impact of the same analytic 
variables as Bliden et al.
7) evaluated (age, body mass in-
dex, diabetes, history of myocardial infarction, hyper-
tension, smoking status, and use of calcium antagonists, 
angiotensin-converting enzyme inhibitors, beta blockers, 
and statins). Age was the only variable that was inverse-
ly correlated with LPPR {odds ratio (OR) 0.904, 95% 
confidence interval (CI) 0.845 to 0.968, p=0.004}. In 
another model of multivariate analyses including vari-
ables with p<0.2 in univariate analyses for differences 
between LPPR vs. non-LPPR groups, age was also the 
only independent predictor of LPPR (OR 0.960, 95% 
CI 0.929 to 0.993, p=0.019) (Table 3). 
 
Discussion 
 
Our study showed that smoking before admission is 
not significantly associated with decreased residual pla-
telet reacti-vity in AMI patients. In addition, we could 
not find a dose-related relationship between smoking 
and postclopidogrel residual platelet reactivity. 
Clopidogrel is a prodrug and can be converted to its 
active metabolite by CYP isoenzymes. Of these, CYP iso-
enzyme 1A2 is activated by the polycyclic aromatic hy-
Table 1. Continued 
Variables, n (%)  Pre-admission smoking (n=97)  Non-smoking (n=37)  p 
Stent diameter (mm)  3.1±0.7 3.0±0.8  <0.421
Stents per patient  1.5±0.8 1.7±0.9  <0.200
Total stent length (mm)  35.9±20.7 41.7±25.8  <0.183
Final TIMI flow grade 3  97 (100)  36 (97.3)  <0.276
BMI: body mass index, STEMI: ST-elevation myocardial infarction, NSTEMI: non-ST-elevation myocardial infarction, PCI: percutaneous 
coronary intervention, CABG: coronary artery bypass grafting, CYP 3A4: cytochrome P450 3A4 isoenzyme, ACEI: angiotensin-converting 
enzyme inhibitor, ARB: angiotensin receptor blocker, LV: left ventricular, Hb: hemoglobin, DTB: door-to-balloon, TIMI: thrombolysis in 
myocardial infarction, GPI: glycoprotein IIb/IIIa inhibitor 
 
Table 2. The rate of LPPR and platelet reactivity according to smoking status
  Non-smoking (n=37) Smoking <0.5 pack/day (n=16) Smoking  ≥0.5 pack/day (n=81)  p
Rate of LPPR, n (%)  5 (13.5)  5 (31.3)  25 (30.9)  0.058
Maximal platelet aggregation (%)         
5μmol/L ADP  48.4±12.5 42.6±16.3 43.8±15.6 0.240
20μmol/L ADP  61.3±11.6 54.8±14.3 56.5±15.9 0.185
Late platelet aggregation (%)         
5μmol/L ADP  38.1±17.3 31.0±20.2 34.3±19.5 0.404
20μmol/L ADP  51.0±18.6 42.1±21.2 46.1±22.8 0.334
Low post-clopidogrel platelet reactivity indicates the lowest quartile of 5μmol/L ADP-induced maximal platelet aggregation (≤37%). LPPR:
low post-clopidogrel platelet reactivity, ADP: adenosine diphosphate 
 
Table 3. Multivariate analysis of predictors for LPPR
Variables  p  OR  95% CI 
Age 0.019  0.960  0.929-0.993
Male 0.932  1.073  0.216-5.319
Pre-admission smoking  0.245  1.916  0.640-5.747
Hemoglobin 0.384  1.179  0.813-1.710
Beta blocker  0.192  2.882  0.588-14.085
Glycoprotein IIb/IIIa inhibitor 0.476  0.586  0.135-2.547
Presence of thrombus  0.845  0.902  0.321-2.535
Stents per patient  0.102  1.555  0.916-2.646
Low post-clopidogrel platelet reactivity indicates the lowest quartile 
of 5μmol/L ADP-induced maximal platelet aggregation (≤37%). 
LPPR: low post-clopidogrel platelet reactivity, OR: odds ratio, CI:
confidence interval 
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drocarbons in cigarette smoke and induced by plasma ni-
cotine.
6)12) Therefore, cigarette smoking induces CYP1A2 
activity and contributes to the increased metabolite of 
clopidogrel in a dose-related manner.
13) Interestingly, 
some reports suggested that smoking might have a good 
effect on short-term clinical outcomes after coronary 
stenting.
14)15) 
However, this suggestion is in opposition to com-
mon knowledge of smoking’s harmfulness. Most epi-
demiologic studies have strongly supported the conclu-
sion that smoking increases the incidence of fatal co-
ronary artery diseases (CAD), especially AMI.
16-20) The 
magnitude of the risk has been linearly related to the 
number of cigarettes smoked, with even low levels of 
smoking being associated with a considerable risk of 
AMI. Increased risk of CAD due to smoking is associ-
ated not only with vasomotor dysfunction but also with 
inflammatory reactions. Thrombosis due to smoking 
has been associated with alterations in platelet func-
tion, antithrombotic/prothrombotic factors, and fibri-
nolytic factors.
21-23) Cigarette smoking induces hyper-
aggregability, decreases the availability of platelet-de-
rived nitric oxide (NO), and decreases platelet sensitivity 
to exogenous NO. Alterations in tissue factors and a con-
sequent increase in thrombotic potential have also been 
documented. Furthermore, higher fibrinogen, higher 
red blood cell counts, higher hematocrits, and higher 
blood viscosity potentiate the prothrombotic process as-
sociated with exposure to smoke. Decreased plasma tis-
sue plasminogen activator activity was observed in smo-
kers. Therefore, smoking is associated with dysfunc-
tional thrombotic mechanisms that promote the initia-
tion and/or propagation of thrombus formation. Com-
pared to chronic CAD, these effects of smoking may play 
a greater role in the setting of AMI. 
Although we could ascertain that smoking may en-
hance clopidogrel-induced platelet inhibition in AMI 
patients, the association seems weaker than the associ-
ation between and elective coronary stenting. In addi-
tion, we did not observe a relationship between the 
number of cigarettes and post-clopidogrel platelet re-
activity. Enhanced platelet reactivity may be a main fea-
ture in the early phase of AMI
24) and correlate with the 
amount of smoking. Because CYP is associated with 
conversion to the active metabolite of clopidogrel, the 
activity of CYP subtypes may be related to the amount 
of the active form of clopidogrel. CYP2C19 contributes 
to both of the two sequential oxidative metabolic steps 
of clopidogrel activation. The polymorphism of this 
subtype can induce loss-of-function to a considerable 
extent.
25)26) Because CYP1A2 affects only the first oxida-
tive step of clopidogrel, induction of CYP1A2 by smok-
ing may have a relatively weak impact on clopidogrel 
activation.
25)26) Furthermore, we assessed residual pla-
telet reactivity at least 3 days after emergency stenting, 
which may be related to a decrease in smoking-induc-
ed CYP1A2 activity. This can explain why smoking did 
not achieve significant suppression of enhanced plate-
let hyperaggregability in this study. 
In the present study, advancing age predicted higher 
post-clopidogrel platelet reactivity in AMI patients. Like 
diabetes mellitus, advancing age shows higher pre-treat-
ment platelet reactivity,
27) which is related to high re-
sidual platelet reactivity. Geisler et al.
28)29) also found 
that patients aged 65 years or older had significantly 
increased residual platelet aggregation at least 6 hours 
after clopidogrel loading. 
A study of the PREDICT score demonstrated that 
various clinical factors influence residual platelet re-
activity (acute coronary syndrome, age >65 years, dia-
betes mellitus, renal failure, and reduced left ventricu-
lar function).
28)29) Because the PS patients showed lower 
prevalence of clinical risk factors in this study, a lower 
platelet reactivity in PS patients might not be expl-
ained by the effect of smoking alone. However, the 
presence of diabetes mellitus and hypertension did not 
induce increased residual platelet reactivity in this study, 
which may be related to the fact that we only enrolled 
AMI patients and we enrolled a small number of subjects. 
 
Limitations 
Our study has several limitations. First, the number 
of study subjects was relatively small. Because there were 
differences in clinical risk factors between PS and NS 
patients, a decreased trend towards maximal platelet 
reactivity in PS patients could not be explained by the 
effect of smoking alone. Second, the study group was 
heterogeneous: it contained both STEMI and NSTE-
MI patients. However, there was no difference in pla-
telet reactivity between these groups. Finally, the time 
point of platelet function measurements can be criti-
cized. Although post-clopidogrel platelet reactivity may 
change dynamically during the early phase of AMI, Ma-
tetzky et al.
9) showed that there may be no significant 
changes of post-clopidogrel platelet reactivity from days 
3 to 5 in AMI patients after coronary stenting. Because 
we assessed platelet reactivity from 3 to 5 days after co-
ronary stenting, our patients’ results may principally re-
flect pre-discharge residual platelet reactivity. 
 
Conclusions 
Smoking before admission is not significantly asso-
ciated with decreased residual platelet reactivity in AMI 
patients. In addition, PS of ≥0.5 pack/day can not in-
duce a significant reduction in post-clopidogrel plate-
let reactivity compared with NS. 
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